The Effect of Omega-3 FA on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Patients
NCT ID: NCT03708887
Last Updated: 2024-07-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
415 participants
INTERVENTIONAL
2020-10-10
2022-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to investigate the effects of n-3 PUFA intervention on glucose and lipid homeostasis in Chinese diabetic/obese patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN)
NCT03120299
Fish Oil-derived Omega-3 Fatty Acids on Gut Microbiota and Lipid Metabolome in Type 2 Diabetes Mellitus
NCT06061510
Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia
NCT01034540
Omega-3 Fatty Acids and Insulin Sensitivity
NCT01686568
The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics
NCT01478776
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose group
Low-dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 1.5 grams per day for 1 year.
Low dose omega-3 fatty acid supplementation
Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year
High dose group
High-dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 3 grams per day for 1 year.
High dose omega-3 fatty acid supplementation
Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
Control group
Control drug, matching placebo capsules, 3 grams per day for 1 year.
Control drug
Matching placebo capsules,3 g/d by mouth for 1 year
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low dose omega-3 fatty acid supplementation
Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year
High dose omega-3 fatty acid supplementation
Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
Control drug
Matching placebo capsules,3 g/d by mouth for 1 year
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI≥28 for obese groups;
* Aged between 40 and 75 years.
Exclusion Criteria
* Cardiovascular disease;
* Cancer;
* Liver or kidney disease;
* Premenopausal women, pregnancy or lactation;
* Allergy to fish;
* Have participated in other clinical trials in the last three months.
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jingjing Jiao
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lanxi Red Cross Hospital
Jinhua, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zhuang P, Wu Y, Yao J, Liu X, Liu H, Wan X, Jia W, Wang T, Zhang Y, Jiao J. Marine n-3 polyunsaturated fatty acids slow sleep impairment progression by regulating central circadian rhythms in type 2 diabetes. Cell Rep Med. 2025 May 20;6(5):102128. doi: 10.1016/j.xcrm.2025.102128. Epub 2025 May 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RCT-N3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.